CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2018--
Therapeutics, Inc. (NASDAQ:MCRB) today announced that the Company
will host a Microbiome R&D Day on Thursday, May 24, 2018, from 8:00
a.m.–10:30 a.m. ET in New York, NY.
The event will feature presentations from Seres management and leading
academic subject matter experts on the microbiome as a new therapeutic
target, with a focus on the Seres pipeline and the opportunity for
microbiome therapeutics to impact immune biology.
Guest speakers scheduled to present at the event include:
Will Dere, M.D., University of Utah Health Sciences Center;
Seres board member
Stephen Hanauer, M.D., Northwestern University Feinberg School
Alan Moss, M.D., Beth Israel Deaconess Medical Center
Jennifer Wargo, M.D., M.M.Sc., MD Anderson Cancer Center
A live audio webcast of the presentation and accompanying slides will be
available under the “Investors and Media” section of Seres’ website. A
replay of the presentation will become available approximately one hour
after the event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. is a leading microbiome therapeutics platform
company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome,
where the state of bacterial diversity and function is imbalanced.
Seres’ lead program, SER-109, has obtained Breakthrough Therapy and
Orphan Drug designations from the U.S. Food and Drug Administration and
is in Phase 3 development for multiply recurrent C. difficile infection.
Seres’ clinical candidate SER-287 has successfully completed a Phase 1b
study in patients with mild-to-moderate Ulcerative Colitis. Seres is
also developing SER-262, the first ever synthetic microbiome therapeutic
candidate, in a Phase 1b study in patients with primary C. difficile
infection. For more information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180517005192/en/
Source: Seres Therapeutics, Inc.
IR or PR Contact:
Carlo Tanzi, Ph.D., 617-203-3467
Investor Relations and Corporate Communications